Francesco Tramutola
University of Basilicata
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Francesco Tramutola.
Journal of Medicinal Chemistry | 2010
Carlo Bonini; Lucia Chiummiento; Margherita De Bonis; Nadia Di Blasio; Maria Funicello; Paolo Lupattelli; Rocco Pandolfo; Francesco Tramutola; Federico Berti
A series of new thienyl ring containing analogues of nelfinavir and saquinavir with different substitution patterns were synthesized from suitable enantiopure diols. Their inhibitory activity against wild type recombinant HIV-1 protease was evaluated. In general thienyl groups spaced from the core by a methylene group gave products showing IC(50) in the nanomolar range, irrespective of the type and the substitution pattern of the heterocycle. The range of activity of the two most active compounds is substantially maintained or even increased against two commonly selected mutants, under drug pressure, such as V32I and V82A.
Bioorganic & Medicinal Chemistry Letters | 2012
Lucia Chiummiento; Maria Funicello; Paolo Lupattelli; Francesco Tramutola; Federico Berti; Francesca Marino-Merlo
Synthesis and biological evaluation of a new series of potential HIV-1 protease inhibitors incorporating different heterocycles are described. The variation of heteroatom in such molecules has displayed totally different biological activities and a benzothiophene containing inhibitor has shown high potency against wild type HIV-1 protease with IC(50)=60 nM, thanks to the lower desolvation penalty to be payed by such hydrophobic moiety.
Organic Letters | 2012
Lucia Chiummiento; Maria Funicello; Paolo Lupattelli; Francesco Tramutola
An effective ligand-free Suzuki coupling protocol to unite methyl (E)-4-bromobut-2-enoate with several arylboronic acids has been accomplished. Thus, a number of variously functionalized methyl 4-arylcrotonates have been achieved in high to excellent yields under mild conditions. This method enables the preparation of diverse aryl-substituted cores of HIV-1 protease inhibitors.
Bioorganic & Medicinal Chemistry | 2014
Carlo Bonini; Lucia Chiummiento; N. Di Blasio; Maria Funicello; Paolo Lupattelli; Francesco Tramutola; Federico Berti; A. Ostric; Stanislav Miertus; Vladimir Frecer; D.-X. Kong
New structurally simple indolic non peptidic HIV Protease inhibitors were synthesized from (S)-glycidol by regioselective methods. Following the concept of targeting the protein backbone, different substitution patterns were introduced onto the common stereodefined isopropanolamine core modifying the type of functional group on the indole, the position of the functional group on the indole and the type of the nitrogen containing group (sulfonamides or perhydroisoquinoline), alternatively. The systematic study on in vitro inhibition activity of such compounds confirmed the general beneficial effect of the 5-indolyl substituents in presence of arylsulfonamide moieties, which furnished activities in the micromolar range. Preliminary docking analysis allowed to identify several key features of the binding mode of such compounds to the protease.
Chemico-Biological Interactions | 2015
Paolo Convertini; Francesco Tramutola; Vito Iacobazzi; Paolo Lupattelli; Lucia Chiummiento; Vittoria Infantino
Anigopreissin A belongs to stilbene di- and oligomeric forms containing a benzofuran ring system whose biological activity is unknown. Recently, a completely protected Anigopreissin A - Permethylated Anigopreissin A - has been synthesized. We use MTT bioassay to assess Permethylated Anigopreissin A cytotoxicity in different human cell lines. Furthermore, fluorescence microscopy, caspase activity, real-time PCR and Western-blot methods are employed to evaluate apoptotic cell death pathway in liver cancer cells. Permethylated Anigopreissin A kills different types of human cancer cells but does not affect non-tumorigenic cells. The Permethylated Anigopreissin A concentration that causes 50% inhibition of liver tumor cells is 0.24μM. Hepatoma cells treated with Permethylated Anigopreissin A arrest their cell cycle in G1 phase. We also demonstrate that Permethylated Anigopreissin A-triggered cell death occurs by apoptosis. Decrease of the BCL2 expression levels, loss of the mitochondrial membrane potential, release of cytochrome c and increase of caspase 9 activity highlight a key role for mitochondria in Permethylated Anigopreissin A-induced apoptosis. Our study shows that Permethylated Anigopreissin A kills liver cancer cells through intrinsic apoptotic pathway.
Chirality | 2012
Lucia Chiummiento; Maria Funicello; Francesco Tramutola
A simple high-yield three-steps route to optically active 4-hydroxymethyl-3-(1H-indolyl)oxazolidin-2-ones from (S)-glycidol is described. The key intermediates (R)-oxiran-2-ylmethyl 1H-indol-4/-5-ylcarbamates are obtained in high yields from (S)-glycidol. These are readily transformed to oxazolidin-2-ones, very interesting building blocks in drug synthesis.
Synthetic Communications | 2015
Maria Funicello; Lucia Chiummiento; Paolo Lupattelli; Francesco Tramutola
Abstract A method for C-Br/C-H bis-phenylation of methyl 4-bromocrotonate via nickel-catalyzed cross-coupling reaction has been developed. This protocol involves commercially available catalyst components and furnishes a suitable doubly phenylated building block. GRAPHICAL ABSTRACT
Tetrahedron | 2009
Lucia Chiummiento; Maria Funicello; Paolo Lupattelli; Francesco Tramutola; Pietro Campaner
Tetrahedron Letters | 2015
Francesco Tramutola; Lucia Chiummiento; Maria Funicello; Paolo Lupattelli
Tetrahedron | 2015
Paolo Lupattelli; Lucia Chiummiento; Maria Funicello; Francesco Tramutola; Antonella Marmo; Natascia Gliubizzi; Daniela Tofani